Value AD
CAN BE
ALTERNATIVE
INVESTMENT
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
PAR-22-131
National Institutes of Health
Funding Opportunity Number: PAR-22-131
Opportunity Category: Discretionary
CFDA Number(s): 93.393 -- Cancer Cause and Prevention Research
Cost Sharing or Matching Requirement: No
Posted Date: Apr 12, 2022 12:00:00 AM EDT
Closing Date: Sep 07, 2025 12:00:00 AM EDT
Award Ceiling: none
Award Floor: none
Eligible Applicants: State governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Others (see text field entitled "Additional Information on Eligibility" for clarification),Private institutions of higher education,County governments,Special district governments,Independent school districts,For profit organizations other than small businesses,Native American tribal organizations (other than Federally recognized tribal governments),City or township governments,Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,Native American tribal governments (Federally recognized),Public housing authorities/Indian housing authorities,Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Agency Name: National Institutes of Health
Description: This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics or glycomic, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.
Grantor Contact Information: NIH OER Webmaster OERWebmaster03@od.nih.gov
